|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in estrogen receptor β gene, ESR2, correlate with colorectal cancer survival.
|
26503819 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Estrogen receptor-β gene polymorphism and colorectal cancer risk: effect modified by body mass index and isoflavone intake.
|
22729816 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We explored the effect modification of MHT-associated CRC risk in postmenopausal women by 47 polymorphisms with known or putative functional relevance in 16 candidate genes related to hormone metabolism (COMT, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP17A1, GSTP, and HSD17B1), transport (ABCB1), and signaling (ESR1, ESR2, SHBG, PGR, and NR1I2).
|
21490239 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The incidence of colorectal cancer was significantly different according to the ESR2 CA repeat genotype only among females (SS, 37/202 = 18.3%; SL, 19/332 = 5.7%; LL, 5/155 = 3.2%, P < 0.0001).
|
21884200 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis.
|
25376484 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ESR2 rs1256049 CT/TT genotypes were associated with reduced risk of CRC (odds ratio [OR], 0.7, 95% confidence interval [CI], 0.5-1.0), while rs4986938 CT/TT genotypes were associated with increased risk of CRC (OR, 1.5, 95% CI, 1.0-2.1).
|
22759347 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival.
|
23149914 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results suggest that hormone use decreases risk for ESR2-positive but not ESR2-negative colorectal cancer.
|
23585455 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the role of ERβ and its association with hormone status and lifestyle indicators in a female cohort of patients with CRC.
|
28763692 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrate that colitis-induced CRC reduced the gut microbiota diversity and that loss of ERβ enhanced this process.
|
30515752 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This raises questions about the role of signalling through other estrogen receptors such as ERα or G-protein coupled estrogen receptor (GPER, GPR30) by the estrogen 17β-estradiol (E2) under hypoxic conditions after ERβ is lost in CRC progression.
|
29137421 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic effect of the treatment for colorectal cancer with adenoviral vectors mediated estrogen receptor β gene therapy combined with thermotherapy.
|
24531912 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study aimed to detect differentially methylated genes associated with ERβ expression, which could point to mechanisms by which ERβ could influence risk and prognosis of CRC.
|
30931802 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified that ERβ exerted an inhibitory effect on CRC tumor proliferation in vitro and in vivo, combined with 5-FU, through up-regulation of MLH1 expression.
|
28404976 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical data support a role for estrogen and its receptors in the initiation and progression of colorectal cancer and establishes that protective effects of estrogen are exerted through ERβ.
|
23965904 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent advances in the molecular biology of CRC, specifically in microsatellite status, estrogen hormone and estrogen receptor beta, have led to greater understanding of the effect of estrogen in colorectal carcinogenesis.
|
19874446 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor β may serve as a target for colorectal cancer prevention.
|
29387989 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings implicate a role of ESR2 in the risk for developing CRC in women and suggest that HSD17B1, ABCB1, and SHBG genes may contribute to sex steroid-mediated effects on CRC development.
|
21317201 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Very little is known, however, about the detailed molecular mechanisms underlying the relationship among ERβ, autophagy, and CyclinD1 in CRC.
|
31182915 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The implications of this pathway include new possibilities to treat or prevent colorectal cancer with targeted endocrine drugs and the potential of ERbeta as a novel diagnostic tool.
|
20663982 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RESULTS We found that the key predictive targets of CC against CRC were estrogen receptor 2 (ESR2), ATP-binding cassette sub-family G member 2 (ABCG2), breast cancer type 1 susceptibility protein (BRCA1), estrogen receptor 1 (ESR1), cytochrome p450 19A1 (CYP19A1), and epidermal growth factor receptor (EGFR).
|
31352466 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is the first observation of correlated reduction of PER1 and ER2 in Chinese colon cancers, and they do play a certain role in colorectal cancer.
|
26339386 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of the expression of CRC promoting/inhibiting genes in duodenal polyps biopsies demonstrated that different CRC-promoting genes (PCNA, MUC1 and COX-2) were significantly downregulated, whereas CRC-inhibiting genes (ER-β and MUC2) were significantly upregulated after ADI treatment.
|
27207660 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
|
15954165 |
2005 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with adjacent non-cancer tissues, the protein level of ERβ was significantly decreased in CRC tissues, and compared with NC the level of miR-129 was significantly increased in blood and tissue samples.
|
29441863 |
2017 |